| Literature DB >> 34903989 |
Maryam Ahmadzadeh1, Hossein Vahidi1, Arash Mahboubi2, Fariba Hajifathaliha2, Leila Nematollahi3, Elham Mohit1.
Abstract
The most common diagnostic method for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR). Upper respiratory tract samples, including nasopharyngeal swab (NPS), oropharyngeal swab (OPS), saliva and lower respiratory tract samples such as sputum, are the most widely used specimens for diagnosis of SARS-CoV-2 using RT-qPCR. This study aimed to compare the diagnostic performance of different samples for Coronavirus disease 2019 (COVID-19) detection. It was found that NPS, the reference respiratory specimen for COVID-19 detection, is more sensitive than OPS. However, the application of NPS has many drawbacks, including challenging sampling process and increased risk of transmission to healthcare workers (HCWs). Saliva samples can be collected less invasively and quickly by HCWs with less contact or by own patients, and they can be considered as an alternative to NPS for COVID-19 detection by RT-qPCR. Additionally, sputum, which demonstrates higher viral load can be applied in patients with productive coughs and negative results from NPS. Commonly, after viral RNA purification from patient samples, which is time-consuming and costly, RT-qPCR is performed to diagnose SARS-CoV-2. Herein, different approaches including physical (heat inactivation) and chemical (proteinase K treatment) methods, used in RNA extraction free- direct RT-qPCR, were reviewed. The results of direct RT-qPCR assays were comparable to the results of standard RT-qPCR, while cost and time were saved. However, optimal protocol to decrease cost and processing time, proper transport medium and detection kit should be determined.Entities:
Keywords: COVID-19; Nasopharyngeal swab; Oropharyngeal swab; RT-qPCR; SARS-CoV-2; Sputum; saliva
Year: 2021 PMID: 34903989 PMCID: PMC8653661 DOI: 10.22037/ijpr.2021.115458.15383
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Different respiratory samples for COVID-19 detection. The respiratory tract samples for COVID-19 detection are divided into the upper (nasopharyngeal swab (NPS)/oropharyngeal swab (OPS), NP wash or saliva) and the lower (sputum) parts
Comparison between self-collected swabs and clinical-collected swabs for diagnosing SARS-CoV-2 using RT-qPCR
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Washington | 185 | Unsupervised home self-collected midnasal swab | 80.0% | 97.9% | Self- | Substantial agreement between technician-collected and patient-collected swabs | ( |
| Clinician-collected NPS | |||||||
| Denmark | 109 | Self-collected OP swabs | 84.2% | - | Self- | Acceptable agreement and almost equivalent sensitivity in technician-collected and patient-collected swabs | ( |
| Clinician-collected OPS | 89.5% | ||||||
| Tehran, Iran | 50 | Patient-collected NPS/OPS | Self- vs. clinician-collected swabs: | Lab technician-collected NP or OPS cannot be replaced by patient-collected ones | ( | ||
| Technician-collected NPS/OPS |
NPS: nasopharyngeal swabs; OPS: oropharyngeal swabs; RT-qPCR: quantitative reverse transcription polymerase chain reaction;
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Comparison between OPS and NPS for diagnosing SARS-CoV-2 using RT-qPCR
|
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|---|
| China | NPS and OPS | 353 | NPS: | - | - | Correlation between NPS and OPS: | Higher positive rate of NPS than OPS for COVID-19 detection | (13) | ||
| OPS: | ||||||||||
| Combined: | ||||||||||
| China | NPS and OPS | 120 | NPS: 46.7% | NPS: 98.3% | NPS: 37.8 | Median duration of COVID-19 detection | Maximum duration of COVID-19 detection | Significant higher sensitivity of NPS than OPS | (20) | |
| NPS: | NPS: | |||||||||
| OPS: 10.0% | OPS: 21.1% | OPS: 39.4 | OPS: | OPS: | ||||||
| Georgia, USA | NPS and OPS | 146 | Collected ≤7 days after illnessonset | NPS: 15.1% | NPS: | NPS (N1): 24.3 | - | The sensitivity of NPS and OPS collecting at >7 days after illness onset was more different than that collected at ≤7 days after illness onset | (12) | |
| OPS (N1): 29.9 | ||||||||||
| OPS: 14.4% | OPS: | |||||||||
| Collected >7 days after illnessonset | NPS: 23.7% | NPS: | - | |||||||
| OPS: 17.0% | OPS: 71.4% | |||||||||
NPS: nasopharyngeal swabs; OPS: oropharyngeal swabs; RT-qPCR: quantitative reverse transcription polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Comparison between saliva/ gargle and swabs for COVID-19 detection using RT-qPCR
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| NPS and saliva | Japan | 196 | - | - | NPS and saliva: 96.4% | The same accuracy of saliva and NPS collected in an acute phase for detection of SARS-CoV-2 using RT-qPCR | (24) | |||
| NPS/OPS,saliva and OR | USA | 570 | Saliva compared with NPSs: | Saliva compared with NPSs: | NPS and saliva: 97.7% | - | - | Mean Ct (N2) in NPS and OPS: | Saliva is an acceptable alternative to NPSs for SARS-CoV-2 RNA detection by RT-qPCR | (22) |
| Saliva compared with OPSs: | Saliva compared with OPSs: | OPS and saliva: 93% | Mean Ct (N2) in saliva: | |||||||
| OR compared with NPS: | ORcompared with NPS: | ORand NPS: | Mean Ct (N2) in OR: | |||||||
| NPS and saliva | United Arab Emirates | 401 | Saliva compared to NPS: | Saliva compared to NPS: | NPS and saliva: 96.0% | 98.1% | 67.9% | Good diagnostic accuracy and feasibility of utilization of specimen without transport media for Saliva | (29) | |
| NPS/OPS and saliva | Brazil | 155 | Saliva compared to NPS/OPS: 94.4% | Saliva compared to NPS/OPS: | NPS/OPS and saliva: | 95.35% | 97.1% | High overall agreement between NPS/OPS and saliva | (28) | |
| NPS/OPS and saliva | Thailand | 150 | Compared to NPS/throat swabs: | Compared to NPS/throat swabs: | NPS/OPS and saliva: | 98.4% | 88.9% | Median Ct (ORF1ab and N) in salvia: | High sensitivity and comparable performance of saliva to NPS/throat swab | (27) |
| Median Ct (ORF1ab and N) in NPS/throat swabs: 32 and 30.5 | ||||||||||
| NPS/OPS and saliva | Singapore | 42 | - | - | NPS and saliva: 69.0% | 52.4% | 95.2% | Ct in saliva: 25.77 ± 5.60 | Moderate agreement between self-collected saliva/buccal swabs and HCW-collected NPS | (33) |
| Ct in NPS: 22.95 ± 6.03 | ||||||||||
| NPS, saliva and gargle | Canada | 50 | Saline mouth rinse/gargle: 98% | - | - | Demonstrating higher combined user acceptability ratings and analytical performance for saline mouth rinse/gargle samples than saliva and HCW-collected NPS | (23) | |||
| Saliva sample: 79% | ||||||||||
| NPS and DTS | China | 95 | - | - | NPS and DTS: | Equivalent overall performance of DTS to that of the NPS | (30) |
DTS: deep throat saliva; HCW: healthcare workers; NPS: nasopharyngeal swabs; NPV: negative predictive value; OPS: oropharyngeal swabs; OR: Oral rinse; PPV: positive predictive value; RT: room temperature; RT-qPCR: quantitative reverse transcription polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Comparison between sputum and swabs for COVID-19 detection by RT-qPCR
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| China | 54 | Throat swabs | 44.2% | - | Significant higherCOVID-19 detection rates from sputum specimens than those from throat swabs | ( |
| Sputum | 76.9% | - | ||||
| China | 20 | Sputum | 95% (19/20) | 42.8 ± 4.2 | More prolonged survival period of SARS-CoV-2in sputum specimens from COVID-19 patients | ( |
| Throat swabs |
| 32.0 | ||||
| Nasal swabs |
| 24.0 | ||||
| China | 132 | Sputum | 48.68% (148/304) |
| Higher detection rate in sputum than NPS | ( |
| NPS | 38.13% (180/472) |
|
COVID-19: Coronavirus disease 2019; NPS: nasopharyngeal swabs; RT-qPCR: quantitative reverse transcription polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Figure 2Schematic representation of standard and direct RT-qPCR. In standard RT-qPCR, respiratory samples were collected, and in the case of swabs, they were transferred into a transport medium. Then, viral RNA was extracted, and an RT-qPCR reaction was performed. In direct RT-qPCR, the virus was inactivated by different methods, including heating, proteinase K treatment, pH changing, and then these inactivated samples were used for COVID-19 detection by RT-qPCR. In this process, time and cost were saved
Different direct RT-qPCR methods for diagnosing SARS-CoV-2 RNA
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| NPS | 597 | Adding Lysis Buffer | 96.0% | 99.8% | 98.8% | ORF1: 0.009 TCID50/mL |
| ( |
| NPS | Pooled patient sample | Heating at 70 °C for 5 min | 95% |
|
| 1.7×104copies RNA/mL | - | ( |
| Saliva | - | Buffer Dilution+ heating at 95 °C for 30 min+ Tween-20 | 88.9% | 98.9% | - | 1,000 copies of SARS-CoV-2 virus per mL of saliva spiked with γ-irradiated SARS-CoV-2 | - | ( |
| NPS | 80 | Heating at 95 ºC for 5 min | Over 90% | - | 95% | - | Saving time: | ( |
| Nasopharyngeal specimens positive for SARS-CoV-2 and other coronaviruses | 132 | 4- fold specimen dilution+ incubation at 65 ˚C | 95% | 99% | 98.5% | 6,600 copies per mL of a viral suspension spiked with synthetic SARS-CoV-2 RNA | - | ( |
| Nasal and pharyngeal swab | 78 | PK (3 μg/μL, 56 ˚C for 10 min) and thermal shock (98 ˚C for 5 min followed by 4 ˚C for 2 min) | - | - | 100% | - | Saving time: 30 min compare to standard RT-qPCR | ( |
| NPS | 90 | Incubation at 70 ˚C + additives in formamide-EDTA (FAE) buffer and RNAsnapTM buffer | 87.8% | 100% | 99.9% | - | Saving time: 1-1.2 h compare to standard RT-qPCR | ( |
| NPS nasalSwab | - | Heating at 75 ˚C for 10 min | - | - | 98% | 550 virus copies/mL of swab | Less than one hour | ( |
| Saliva | - | Incubation in an alkaline-glycol solution samples (pH 12.2 to 12.8) | 32-foldincrease in detectionsensitivity by AG processing | - | - | 300 copies per mL of saliva | - | ( |
| Sputum and nasal exudate | - | Dithiothreitol (Sputasol) + ribonuclease inhibitor | - | - | - | 12 copies per PCR reaction volume | 36 min | ( |
| Throat swabsand other materials from the respiratory | - | PK treatment + repetitive heating steps (56 ˚C for 3 min and then at 95 ˚C for 3 min) | 94.6% | - | - | 5–10genome per mL | 90 min | ( |
Ct: cycle threshold; NPS: nasopharyngeal swabs; PK: Proteinase K; RT: room temperature; RT-qPCR: quantitative reverse transcription polymerase chain reaction; UVT: universal viral transport.